G-CSF 和 G-CSF 生物相似药市场规模、份额和成长分析：按药物类型、治疗应用、通路和地区划分－2026-2033 年产业预测

2024年全球G-CSF和G-CSF生物相似药市场价值为56亿美元，预计将从2025年的60.3亿美元成长到2033年的108.3亿美元。预测期（2026-2033年）的复合年增长率预计为7.6%。

全球粒细胞集落刺激因子 (G-CSF) 及其生物相似药市场的主要驱动力是原生物製药专利到期以及对价格合理的肿瘤支持治疗日益增长的需求。已上市的 G-CSF 产品已展现出显着的临床疗效，推动了 Zarchio 和 Udenica 等生物相似药的出现。这些生物相似药促进了价格竞争，并扩大了患者的用药范围。这种转变使市场对价格更加敏感，促使医院采用成本较低的生物相似药。因此，治疗依从性提高，住院率下降。此外，人工智慧的应用改善了需求预测和生产流程，提高了营运效率，进一步降低了价格。因此，该市场对生产投资和新兴应用的探索更具吸引力，为该领域的可持续成长铺平了道路。

推动全球G-CSF和G-CSF生物相似药市场发展的因素

癌症患者数量的不断增长，以及骨髓抑制化疗的广泛应用，显着增加了临床上对预防和治疗化疗引起的嗜中性白血球低下症治疗方法的需求。这一趋势正在推动粒细胞集落刺激因子（G-CSF）及其生物相似药市场的成长。临床指引和医疗机构的实践强调了预防性和治疗性给药对于维持治疗强度和最大限度降低感染风险的重要性，从而导致处方频率的增加。此外，随着临床医师对生物相似药的了解不断加深，以及医疗机构采用整合这些药物的通讯协定，未被满足的医疗需求正得到有效满足，从而推动市场持续扩张。

全球粒细胞集落刺激因子（G-CSF）和G-CSF生物相似药市场面临的限制因素

全球粒细胞集落刺激因子（G-CSF）及其生物相似药市场面临许多挑战，主要原因是各国对相似性的监管要求复杂多样，且在互通性方面标准不一。这些因素造成了复杂的局面，可能阻碍潜在研发者的积极性，并延缓产品进入各个市场。研发者需要进行全面的对比试验，履行核准后监测职责，并适应不断变化的法规，所有这些都需要延长研发週期，并持续投入资金用于证据收集和与监管机构沟通。这种复杂的核准流程最终阻碍了新生物相似药的上市，并限制了可能推动市场更广泛渗透和成长的竞争动力。

全球粒细胞集落刺激因子（G-CSF）及G-CSF生物相似药市场趋势

全球粒细胞集落刺激因子（G-CSF）及其生物相似药市场正经历着向门诊治疗的显着转变，这主要得益于医疗系统和肿瘤中心将支持性治疗转移到家庭环境中。这一趋势优先考虑患者的便利性，旨在减少住院需求，迫使生产商创新给药配方、开发个人化患者支持方案并加强门诊治疗的物流保障。此外，专业药局与医疗服务提供者之间的合作对于确保患者用药依从性和监测至关重要。随着分散式治疗逐渐成为标准，人们对整个G-CSF价值链的稳定性、易用性和一体化服务的要求也日益提高，从而影响着市场动态。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球粒细胞集落刺激因子 (G-CSF) 及 G-CSF 生物相似药市场规模：按药物类型和复合年增长率 (2026-2033) 划分

• G-CSF
• 生物相似药
• 荷尔蒙
• 其他的

全球粒细胞集落刺激因子 (G-CSF) 及 G-CSF 生物相似药市场规模：依治疗应用及复合年增长率 (2026-2033) 划分

• 肿瘤学
• 血液疾病
• 慢性病
• 内分泌疾病
• 其他的

全球粒细胞集落刺激因子 (G-CSF) 及 G-CSF 生物相似药市场规模：按分销管道和复合年增长率 (2026-2033) 划分

• 网路药房
• 离线
  • 医院药房
  • 零售药房

全球粒细胞集落刺激因子及粒细胞集落刺激因子生物相似药市场规模及复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Mylan NV
• Pfizer Inc.
• BioGeneriX AG
• Intas Pharmaceuticals Ltd.
• Biocon Limited
• Celltrion Healthcare Co., Ltd.
• Fresenius Kabi AG
• Zydus Cadila
• Accord Healthcare Limited
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Novartis AG
• Coherus BioSciences, Inc.
• Emcure Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Samsung Bioepis Co., Ltd.
• GSK plc

结论与建议

Global G-Csf And G-Csf Biosimilars Market size was valued at USD 5.6 Billion in 2024 and is poised to grow from USD 6.03 Billion in 2025 to USD 10.83 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The global G-CSF and G-CSF biosimilars market is primarily propelled by the expiration of patents for original biologics and the increasing demand for accessible supportive oncology care. Established G-CSF products have shown significant clinical benefits, enabling the emergence of biosimilars like Zarxio and Udenyca, which foster competitive pricing and broaden patient access. This shift has transformed the market into a price-sensitive arena, encouraging hospitals to adopt lower-cost biosimilars, resulting in better treatment adherence and reduced hospitalization rates. Additionally, the integration of AI enhances operational efficiencies by improving demand forecasting and manufacturing processes, further supporting affordability. As a result, the market becomes more attractive for production investments and exploration of emerging applications, paving the way for sustained growth in the sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global G-Csf And G-Csf Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global G-Csf And G-Csf Biosimilars Market Segments Analysis

Global g-csf and g-csf biosimilars market is segmented by drug type, therapeutic application, distribution channel and region. Based on drug type, the market is segmented into G-CSF, Biosimilars, Hormones and Others. Based on therapeutic application, the market is segmented into Oncology, Blood Disorders, Chronic Diseases, Endocrine Disorders and Others. Based on distribution channel, the market is segmented into Online Pharmacies and Offline. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global G-Csf And G-Csf Biosimilars Market

The increasing prevalence of cancer, coupled with the extensive use of myelosuppressive chemotherapy, has significantly heightened the clinical demand for treatments that prevent and manage chemotherapy-induced neutropenia. This trend is driving growth in the G-CSF and biosimilars market. Clinical guidelines and the practices of healthcare providers highlight the importance of both preventive and therapeutic administration to sustain treatment intensity and minimize the risk of infections, leading to more frequent prescriptions. Additionally, as clinicians become more acquainted with biosimilar options and institutions adopt protocols integrating these drugs, unmet clinical needs are being effectively addressed, resulting in sustained market expansion.

Restraints in the Global G-Csf And G-Csf Biosimilars Market

The Global G-CSF and G-CSF biosimilars market faces significant challenges due to complex and varied regulatory requirements for demonstrating similarity, coupled with differing national standards for interchangeability. These factors contribute to an intricate landscape that can discourage potential developers and delay the introduction of products to various markets. Developers are required to create comprehensive comparative studies, fulfill post-approval monitoring responsibilities, and adapt to constantly changing regulations, all of which can extend development timelines and necessitate ongoing investments in both evidence generation and regulatory dialogue. This intricate approval process ultimately hinders the entry of new biosimilars, limiting competitive dynamics that could otherwise drive broader adoption and growth in the market.

Market Trends of the Global G-Csf And G-Csf Biosimilars Market

The Global G-Csf and G-Csf Biosimilars market is witnessing a significant shift towards outpatient therapies, driven by healthcare systems and oncology centers transitioning supportive care to home-based settings. This trend prioritizes patient convenience and aims to reduce inpatient demand, prompting manufacturers to innovate delivery formats, create tailored patient support programs, and enhance logistics for ambulatory care. Additionally, partnerships between specialty pharmacies and healthcare providers are becoming essential to ensure patient adherence and monitoring. As decentralized care becomes the norm, there is an increasing expectation for stability, ease of use, and integrated services throughout the G-Csf value chain, shaping market dynamics.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global G-CSF and G-CSF Biosimilars Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• G-CSF
• Biosimilars
• Hormones
• Others

Global G-CSF and G-CSF Biosimilars Market Size by Therapeutic Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Blood Disorders
• Chronic Diseases
• Endocrine Disorders
• Others

Global G-CSF and G-CSF Biosimilars Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Online Pharmacies
• Offline
  • Hospital Pharmacies
  • Retail Pharmacies

Global G-CSF and G-CSF Biosimilars Market Size & CAGR (2026-2033)

• North America (Drug Type, Therapeutic Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Therapeutic Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Therapeutic Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Therapeutic Application, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Therapeutic Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGeneriX AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Healthcare Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emcure Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations